Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predeces
October 01 2009 - 12:00PM
PR Newswire (US)
Company Makes Announcement at a Meeting of Southeastern
Reproductive Health Organizations FHC Makes Special Commitment to
Expand Access in U.S. Regions with Highest AIDS Case Rates CHICAGO,
Oct. 1 /PRNewswire-FirstCall/ -- The Female Health Company (FHC)
(NASDAQ:FHCO) announced today that its second-generation FC2 Female
Condom®, which received regulatory approval from the Food and Drug
Administration in March as an HIV prevention method, is now
available for purchase in the United States. The company made the
announcement in Atlanta at a meeting of the Southeastern Urban
Initiative for Reproductive Health, a coalition of reproductive
health advocates from Southern states that is advocating for
increased federal funding for HIV prevention. "America's HIV
epidemic isn't going away. In fact, it's getting worse, and African
American and Latino women are disproportionately impacted," said
Dazon Dixon Diallo, Founder and President of SisterLove, a
grassroots service organization that supports HIV/AIDS prevention
and reproductive health programs for women in the Atlanta, Georgia
region. "It's time to provide women in heavily impacted communities
with expanded access to affordable women-controlled options, and
the female condom becomes that choice. Women will use it if they
have it." "We're thrilled that FC2 is now available in the United
States," said Mary Ann Leeper, FHC's senior strategic adviser, who
will deliver a keynote address on the female condom and
woman-initiated prevention at the Atlanta meeting. "We developed
the female condom to provide women with access to HIV prevention
that they can initiate. We know that women and men practice safer
sex when they have access to more prevention methods, and we
believe that access to the female condom can help millions of
American women negotiate safer sex with their partners." FC2 may be
purchased from the Company's two public sector distributors: Total
Access Group, Inc. http://www.totalaccessgroup.com/ and Global
Protection Corporation, http://www.globalprotection.com/store. In
addition, FHC has launched a website,
http://www.fc2femalecondom.com/, which includes tiered pricing
information for ordering a minimum quantity of 25,000 units
directly from the Company. Price per unit declines based on the
volume purchased. It is important to note that the maximum price to
purchase FC2 from the Company's distributors is $0.82/unit
regardless of quantity, approximately a 30% decrease from the price
paid for FC1. FHC Makes Commitment to Expanded Access and Education
Seven of the top 10 states ranked by the rate of AIDS cases are in
the U.S. South. FHC is initiating a program to work with a number
of southern reproductive health service organizations to provide
free allotments of FC2 Female Condoms as part of an introductory
awareness and education program, including training for health
providers on how to integrate female condom education into
reproductive health counseling. Data from the Centers for Disease
Control and Prevention (CDC) show that women represent a growing
proportion of Americans living with HIV and AIDS. Over the past two
decades, the percentage of women among all people living with HIV
in the U.S. has increased from 8 percent to 27 percent. African
American and Latino women are also disproportionately impacted by
the epidemic. African American women account for 66 percent of new
AIDS cases among American women, while Latino women are five times
more likely than white women to be diagnosed with AIDS. The AIDS
case rate is significantly higher in the U.S. South than in other
regions of the country, and the prevalence of HIV and AIDS cases in
some southern communities is comparable to prevalence figures for
West Africa. More than 70 reproductive health and HIV/AIDS advocacy
organizations in the U.S. have called on donors and implementing
agencies to expand women's access to the female condom, which
remains the only safe and effective method of woman-initiated HIV
prevention currently available. FC2 will be available in certain
retail outlets. As previously announced, FHC is seeking a partner
with appropriate experience to promote FC2 directly to consumers in
the US. About The Female Health Company The Female Health Company
(FHC), headquartered in Chicago, IL, is the maker of the FC Female
Condom (FC1 and FC2), a revolutionary option offering women dual
protection against both sexually transmitted diseases, including
HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide
company in February 1996 with the purchase of Chartex Resources
Ltd., the holder of exclusive worldwide rights to FC1. The Company
holds exclusive product and technology patents for FC1 in the
United States, Australia, Brazil, Canada, France, Germany, Italy,
Spain, the United Kingdom, the People's Republic of China, South
Korea and Japan. FC2 patents have been granted in Australia and
South Africa and are pending in various other countries. FHC is the
sole manufacturer and marketer of the FC1 and FC2 female condoms in
the world. The Female Health Company and its partners currently
market the Female Condom under FCFemale Condom®, FC2 Female
Condom®, Reality®, Femidom®, Femy®, and Care®. "Safe Harbor"
statement under the Private Securities Litigation Reform Action of
1995: The statements in this release which are not historical facts
are forward-looking statements based upon the Company's current
plans and strategies, and reflect the Company's current assessment
of the risks and uncertainties related to its business, including
such things as product demand and market acceptance; the economic
and business environment and the impact of government pressures;
currency risks; capacity; efficiency and supply constraints; and
other risks detailed in the Company's press releases, shareholder
communications and Securities and Exchange Commission filings.
Actual events affecting the Company and the impact of such events
on the Company's operations may vary from those currently
anticipated. DATASOURCE: Female Health Company CONTACT: Media:
Bryan Callahan, +1-202-729-4255, Product Information: Mary Ann
Leeper, +1-434-964-1488, Investor Contacts: Donna Felch,
+1-312-595-9123, or William R. Gargiulo, Jr., +1-231-526-1244, all
of Female Health Company Web Site: http://www.totalaccessgroup.com/
https://www.globalprotection.com/ http://www.fc2femalecondom.com/
Copyright